A 63-year-old woman with type 2 diabetes, prior myocardial infarction and an HbA1c of 7.6% on maximally tolerated metformin presents for review. eGFR is 55 mL/min/1.73 m². According to Canadian guidelines, which is the most appropriate next pharmacologic step to reduce future cardiovascular events?